TABLE 2.
Comparison of rezafungin MICs to those of other licensed antifungal agents for 1,293 contemporary Nordic clinical Candida isolates and 122 C. auris isolates from India
| Species | Rezafungin |
Anidulafungin |
Micafungin |
Amphotericin B |
Fluconazole |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC range (mg/liter) | Modal MIC (mg/liter) | % (n) >WT-UL | MIC range (mg/liter) | Modal MIC (mg/liter) | % (n) >ECOFF | MIC range (mg/liter) | Modal MIC | % (n) >ECOFF | MIC range (mg/liter) | Modal MIC (mg/liter) | % (n) >ECOFF | MIC range (mg/liter) | Modal MIC (mg/liter) | % (n) >ECOFF | |
| Nordic clinical isolates | |||||||||||||||
| C. albicans | 0.016 to 1 | 0.06 | 1.9 (11) | 0.004 to 0.25 | 0.004 | 1.1 (6) | 0.004 to 2 | 0.016 | 6.2 (35)a | 0.06 to 0.5 | 0.25 | 0 (0)a | 0.03 to >64 | 0.125 | 5.6 (32)a |
| C. glabrata | 0.03 to 2 | 0.125 | 3.0 (10) | 0.008 to 1 | 0.03 | 3.3 (11) | 0.008 to 0.5 | 0.016 | 4.9 (16) | 0.03 to 1 | 0.25 | 0 (0)a | 0.5 to >64 | 4 | 8.2 (27)a |
| C. krusei | 0.03 to 1 | 0.125 | 1.2 (1) | 0.016 to 0.25 | 0.03 | 2.4 (2) | 0.06 to 4 | 0.125 | 3.7 (3) | 0.5 to 1 | 0.5 | 0 (0) | 8 to >64 | 16 | ND |
| C. tropicalis | 0.03 to 2 | 0.125 | 2.7 (2) | 0.008 to 2 | 0.03 | 2.7 (2) | 0.016 to 2 | 0.03 | 2.7 (2) | 0.125 to 1 | 0.25 | 0 (0) | 0.125 to >64 | 0.5 | 8.2 (6) |
| C. dubliniensis | 0.03 to 2 | 0.125 | 2.9 (2) | 0.004 to 0.25 | 0.008 | 2.9b (2) | 0.08 to 2 | 0.03 | 2.9b (2) | 0.03 to 0.25 | 0.06 | 0b (0) | 0.06 to 64 | 0.125 | 5.9b (4) |
| C. parapsilosis | 1 to 4 | 2 | 0 (0) | 0.25 to 2 | 1 | 0 (0) | 0.25 to 4 | 2 | 0 (0) | 0.125 to 1 | 0.5 | 0 (0) | 0.25 to 64 | 0.5 | 4.9 (3) |
| C. lusitaniae | 0.125 to 0.4 | 0.125 | 0 (0) | 0.03 to 0.25 | 0.03 | 5.0b (1) | 0.03 to 0.5 | 0.06 | 5.0b (1) | 0.06 to 1 | 0.125 | 5.0b (1) | 0.25 to 32 | 0.5 | 10.0b (2) |
| S. cerevisiae | 0.125 to 0.5 | 0.25 | 0 (0) | 0.016 to 0.125 | 0.06 | 0b (0) | 0.06 to 0.25 | 0.125 | 0b (0) | 0.03 to 1 | 0.25 | 0b (0) | 0.25 to 32 | 8 | 0b (0) |
| Other Candida | 0.03 to >4 | 0.06 | NDf | 0.004 to 4 | 0.25 | ND | 0.016 to 0.5 | 0.25 | ND | 0.06 to >4 | 0.25 | ND | 0.25 to >64 | 0.25 | ND |
| Other yeast | 0.03 to >4 | >4 | ND | 0.004 to >4 | >4 | ND | 0.008 to >4 | >4 | ND | 0.03 to 2 | 0.25 | ND | 0.125 to >64 | 4 | ND |
| Indian clinical isolates | |||||||||||||||
| C. auris | 0.06 to 16 | 0.25 | 14.8c (18) | 0.016 to >32 | 0.06 | 27.0c (33)a | 0.03 to >32 | 0.125 | 6.6c (8) | 0.5 to 1 | 1 | 0d (0)a | 0.5 to >64 | >64 | 99.2e (121)a |
a
The proportion of non-wild-type strains is significantly different from that for rezafungin (P < 0.05).
b
Percent greater than the WT-UL based upon the MICs for the contemporary Nordic clinical isolates included in this study.
c
Percent greater than the WT-UL (statistical 97.5%) based on 122 clinical C. auris isolates from India (Table 3).
d
Percent greater than the WT-UL (visual).
e
For fluconazole, non-species-specific Candida sp. breakpoints have been set by EUCAST (susceptible, ≤2 mg/liter; resistant, >4 mg/liter).
f
ND, not done.